References
- Craig DW, O’Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013;12(1):104–16. doi:https://doi.org/10.1158/1535-7163.MCT-12-0781
- Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts. Am J Clin Pathol. 2014;141(4):462–77. doi:https://doi.org/10.1309/AJCPQN8GZ8SILKGN
- Lu JY, Schneider RJ. Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem. 2004;279(13):12974–9. doi:https://doi.org/10.1074/jbc.M310433200
- Dean JLE, Sully G, Wait R, Rawlinson L, Clark AR, Saklatvala J. Identification of a novel AU-rich-element-binding protein which is related to AUF1. Biochem J. 2002;366(Pt 3):709–19. doi:https://doi.org/10.1042/BJ20020402
- Pereira B, Billaud M, Almeida R. RNA-binding proteins in cancer: Old players and new actors. Trends Cancer. 2017;3(7):506–28. doi:https://doi.org/10.1016/j.trecan.2017.05.003
- Qin H, Ni H, Liu Y, Yuan Y, Xi T, Li X, Zheng L. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):90. doi:https://doi.org/10.1186/s13045-020-00927-w
- Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem. 1996;271(14):8144–51. doi:https://doi.org/10.1074/jbc.271.14.8144
- Wang J, Guo Y, Chu H, Guan Y, Bi J, Wang B. Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis. Int J Mol Sci. 2013;14(5):10015–41. doi:https://doi.org/10.3390/ijms140510015
- Dai W, Zhang G, Makeyev EV. RNA-binding protein HuR autoregulates its expression by promoting alternative polyadenylation site usage. Nucleic Acids Res. 2012;40(2):787–800. doi:https://doi.org/10.1093/nar/gkr783
- Akaike Y, Masuda K, Kuwano Y, Nishida K, Kajita K, Kurokawa K, Satake Y, Shoda K, Imoto I, Rokutan K, et al. HuR regulates alternative splicing of the TRA2β gene in human colon cancer cells under oxidative stress. Mol Cell Biol. 2014;34(15):2857–73. doi:https://doi.org/10.1128/MCB.00333-14
- Mukherjee N, Corcoran DL, Nusbaum JD, Reid DW, Georgiev S, Hafner M, Ascano M, Tuschl T, Ohler U, Keene JD, et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell. 2011;43(3):327–39. doi:https://doi.org/10.1016/j.molcel.2011.06.007
- Fan XC, Steitz JA. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci U S A. 1998;95(26):15293–8. doi:https://doi.org/10.1073/pnas.95.26.15293
- Hasegawa H, Kakuguchi W, Kuroshima T, Kitamura T, Tanaka S, Kitagawa Y, Totsuka Y, Shindoh M, Higashino F. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells. Br J Cancer. 2009;100(12):1943–8. doi:https://doi.org/10.1038/sj.bjc.6605084
- Levidou G, Kotta-Loizou I, Tasoulas J, Papadopoulos T, Theocharis S. Clinical significance and biological role of HuR in head and neck carcinomas. Dis Markers. 2018;2018:4020937. doi:https://doi.org/10.1155/2018/4020937
- Wang H, Ding N, Guo J, Xia J, Ruan Y. Dysregulation of TTP and HuR plays an important role in cancers. Tumour Biol. 2016;37(11):14451–61. doi:https://doi.org/10.1007/s13277-016-5397-z
- Kotta-Loizou I, Giaginis C, Theocharis S. Clinical significance of HuR expression in human malignancy. Med Oncol. 2014;31(9):161. doi:https://doi.org/10.1007/s12032-014-0161-y
- Yuan Z, Sanders AJ, Ye L, Jiang WG. HuR, a key post-transcriptional regulator, and its implication in progression of breast cancer. Histol Histopathol. 2010;25(10):1331–40. doi:https://doi.org/10.14670/HH-25.1331
- Heinonen M, Bono P, Narko K, Chang S-H, Lundin J, Joensuu H, Furneaux H, Hla T, Haglund C, Ristimäki A, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005;65(6):2157–61. doi:https://doi.org/10.1158/0008-5472.CAN-04-3765
- Heinonen M, Fagerholm R, Aaltonen K, Kilpivaara O, Aittomäki K, Blomqvist C, Heikkilä P, Haglund C, Nevanlinna H, Ristimäki A, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res. 2007;13(23):6959–63. doi:https://doi.org/10.1158/1078-0432.CCR-07-1432
- Gubin MM, Calaluce R, Davis JW, Magee JD, Strouse CS, Shaw DP, Ma L, Brown A, Hoffman T, Rold TL, et al. Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis. Cell Cycle. 2010;9(16):3337–46. doi:https://doi.org/10.4161/cc.9.16.12711
- Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M, et al. Critical roles of long noncoding RNAs in breast cancer. J Cell Physiol. 2020;235(6):5059–71. doi:https://doi.org/10.1002/jcp.29442
- Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M, et al. MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. J Cell Physiol. 2020;235(6):5008–29. doi:https://doi.org/10.1002/jcp.29396
- Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009;6(5):575–83. doi:https://doi.org/10.4161/rna.6.5.10079
- Guo X, Connick MC, Vanderhoof J, Ishak MA, Hartley RS. MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int J Mol Sci. 2015;16(4):7112–32. doi:https://doi.org/10.3390/ijms16047112
- Wu P, Gao W, Su M, Nice EC, Zhang W, Lin J, Xie N. Adaptive mechanisms of tumor therapy resistance driven by tumor microenvironment. Front Cell Dev Biol. 2021;9:641469. doi:https://doi.org/10.3389/fcell.2021.641469
- Zhou F, Zhang F, Zhou C, Liang M, Cai Z, Lv H, Li W, Wei X. Human antigen R and drug resistance in tumors. Invest New Drugs. 2019;37(5):1107–16. doi:https://doi.org/10.1007/s10637-018-00723-x
- Hostetter C, Licata LA, Witkiewicz A, Costantino CL, Yeo CJ, Brody JR, Keen JC. Cytoplasmic accumulation of the RNA binding protein HuR is central to tamoxifen resistance in estrogen receptor positive breast cancer cells. Cancer Biol Ther. 2008;7(9):1496–506. doi:https://doi.org/10.4161/cbt.7.9.6490
- Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, Muralidharan R, Gorospe M, Herman T, Ding W-Q, et al. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy. Oncotarget. 2016;7(40):64820–35. doi:https://doi.org/10.18632/oncotarget.11706
- Andrade D, Mehta M, Griffith J, Oh S, Corbin J, Babu A, De S, Chen A, Zhao YD, Husain S, et al. HuR reduces radiation-induced DNA damage by enhancing expression of ARID1A. Cancers (Basel.). 2019;11(12):2014. doi:https://doi.org/10.3390/cancers11122014
- Kuwano Y, Kim HH, Abdelmohsen K, Pullmann R, Martindale JL, Yang X, Gorospe M. MKP-1 mRNA stabilization and translational control by RNA-binding proteins HuR and NF90. Mol Cell Biol. 2008;28(14):4562–75. doi:https://doi.org/10.1128/MCB.00165-08
- Pang X, Gong K, Zhang X, Wu S, Cui Y, Qian B-Z. Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharmacol Res. 2019;144:235–44. doi:https://doi.org/10.1016/j.phrs.2019.04.030
- Jiang D, Chen F-X, Zhou H, Lu Y-Y, Tan H, Yu S-J, Yuan J, Liu H, Meng W, Jin Z-B, et al. Bioenergetic crosstalk between mesenchymal stem cells and various ocular cells through the intercellular trafficking of mitochondria. Theranostics. 2020;10(16):7260–72. doi:https://doi.org/10.7150/thno.46332
- Burkhart RA, Pineda DM, Chand SN, Romeo C, Londin ER, Karoly ED, Cozzitorto JA, Rigoutsos I, Yeo CJ, Brody JR, et al. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer. RNA Biol. 2013;10(8):1312–23. Augdoi:https://doi.org/10.4161/rna.25274
- Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123(3):725–31. ‐doi:https://doi.org/10.1007/s10549-009-0674-9
- Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res. 1987;47(4):936–42. ‐
- Prasad CP, Chaurasiya SK, Guilmain W, Andersson T. WNT5A signaling impairs breast cancer cell migration and invasion via mechanisms independent of the epithelial-mesenchymal transition. J Exp Clin Cancer Res. 2016;35(1):144. doi:https://doi.org/10.1186/s13046-016-0421-0
- Wu X, Gardashova G, Lan L, Han S, Zhong C, Marquez RT, Wei L, Wood S, Roy S, Gowthaman R, et al. Targeting the interaction between RNA-binding protein HuR and FOXQ1 suppresses breast cancer invasion and metastasis. Commun Biol. 2020;3(1):193. doi:https://doi.org/10.1038/s42003-020-0933-1
- Schultz CW, Preet R, Dhir T, Dixon DA, Brody JR. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR). Wiley Interdiscip Rev RNA. 2020;11(3):e1581. doi:https://doi.org/10.1002/wrna.1581
- Chae M-J, Sung HY, Kim E-H, Lee M, Kwak H, Chae CH, Kim S, Park W-Y. Chemical inhibitors destabilize HuR binding to the AU-rich element of TNF-alpha mRNA. Exp Mol Med. 2009;41(11):824–31. doi:https://doi.org/10.3858/emm.2009.41.11.088
- Ritch SJ, Brandhagen BN, Goyeneche AA, Telleria CM. Advanced assessment of migration and invasion of cancer cells in response to mifepristone therapy using double fluorescence cytochemical labeling. BMC Cancer. 2019;19(1):376. doi:https://doi.org/10.1186/s12885-019-5587-3
- Shen T, Zhang K, Siegal GP, Wei S. Prognostic Value of E-Cadherin and β-Catenin in Triple-Negative Breast Cancer. Am J Clin Pathol. 2016;146(5):603–10. doi:https://doi.org/10.1093/ajcp/aqw183
- Jin J, Krishnamachary B, Mironchik Y, Kobayashi H, Bhujwalla ZM. Phototheranostics of CD44-positive cell populations in triple negative breast cancer. Sci Rep. 2016;6:27871. doi:https://doi.org/10.1038/srep27871
- Liu L, Christodoulou-Vafeiadou E, Rao JN, Zou T, Xiao L, Chung HK, Yang H, Gorospe M, Kontoyiannis D, Wang J-Y, et al. RNA-binding protein HuR promotes growth of small intestinal mucosa by activating the Wnt signaling pathway. Mol Biol Cell. 2014;25(21):3308–18. doi:https://doi.org/10.1091/mbc.E14-03-0853
- Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429–34. Pt 1):doi:https://doi.org/10.1158/1078-0432.CCR-06-3045
- Hou J, Zhou Z, Chen X, Zhao R, Yang Z, Wei N, Ni Q, Feng Y, Yu X, Ma J, et al. HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo. Oncotarget. 2016;7(29):45186–98. doi:https://doi.org/10.18632/oncotarget.9870
- Davidson B, Holth A, Hellesylt E, Hadar R, Katz B, Tropé CG, Reich R. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival. Hum Pathol. 2016;48:95–101. doi:https://doi.org/10.1016/j.humpath.2015.09.027
- Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. Prognostic value of the human antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. Anticancer Res. 2011;31(1):303–10.
- Shahi Thakuri P, Gupta M, Singh S, Joshi R, Glasgow E, Lekan A, Agarwal S, Luker GD, Tavana H. Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling. BMC Cancer. 2020;20(1):4. doi:https://doi.org/10.1186/s12885-019-6479-2
- Chekalina N, Burmak Y, Petrov Y, Borisova Z, Manusha Y, Kazakov Y, Kaidashev I. Quercetin reduces the transcriptional activity of NF-kB in stable coronary artery disease. Indian Heart J. 2018;70(5):593–7. doi:https://doi.org/10.1016/j.ihj.2018.04.006
- Maurya AK, Vinayak M. PI-103 and quercetin attenuate PI3K-AKT signaling pathway in T- Cell Lymphoma Exposed to Hydrogen Peroxide. PLoS One. 2016;11(8):e0160686. doi:https://doi.org/10.1371/journal.pone.0160686
- Smith SM, Lyu YL, Cai L. NF-κB affects proliferation and invasiveness of breast cancer cells by regulating CD44 expression. PLoS One. 2014;9(9):e106966. doi:https://doi.org/10.1371/journal.pone.0106966